FilingSEC EDGAR6-K
Rodman & Renshaw initiates coverage on Quantum BioPharma with a Buy rating.
· SEC accepted
StageInitiation
Filing content
The analyst firm initiated coverage on Quantum BioPharma with a Buy rating and a price target of $8.
AI summary of the filing. Please also check the source.Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…